Syros Pharmaceuticals (NASDAQ:SYRS) Issues Quarterly Earnings Results

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($0.76) by $0.08, Zacks reports. During the same quarter in the prior year, the business earned ($1.35) EPS.

Syros Pharmaceuticals Stock Performance

SYRS stock traded down $0.25 during trading on Friday, reaching $2.27. The stock had a trading volume of 523,534 shares, compared to its average volume of 242,872. The firm has a market cap of $60.72 million, a PE ratio of -0.73 and a beta of 1.59. The company has a current ratio of 3.46, a quick ratio of 3.46 and a debt-to-equity ratio of 1.97. The stock's 50 day moving average is $1.91 and its two-hundred day moving average is $3.99. Syros Pharmaceuticals has a 52 week low of $1.43 and a 52 week high of $8.17.

Insider Buying and Selling at Syros Pharmaceuticals

In other Syros Pharmaceuticals news, CFO Jason Haas acquired 45,344 shares of the company's stock in a transaction that occurred on Thursday, September 12th. The shares were bought at an average price of $1.68 per share, with a total value of $76,177.92. Following the completion of the acquisition, the chief financial officer now owns 124,552 shares in the company, valued at $209,247.36. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Conley Chee purchased 50,000 shares of Syros Pharmaceuticals stock in a transaction on Tuesday, September 10th. The stock was acquired at an average price of $1.51 per share, for a total transaction of $75,500.00. Following the completion of the transaction, the chief executive officer now directly owns 72,504 shares in the company, valued at $109,481.04. This represents a 200.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Jason Haas acquired 45,344 shares of the stock in a transaction dated Thursday, September 12th. The shares were bought at an average cost of $1.68 per share, for a total transaction of $76,177.92. Following the completion of the transaction, the chief financial officer now owns 124,552 shares in the company, valued at approximately $209,247.36. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 130,707 shares of company stock worth $206,491 in the last three months. 12.26% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have commented on SYRS shares. JMP Securities reduced their target price on Syros Pharmaceuticals from $12.00 to $4.00 and set a "market outperform" rating for the company in a report on Tuesday, August 13th. HC Wainwright reiterated a "buy" rating and issued a $6.00 price objective on shares of Syros Pharmaceuticals in a report on Friday. Piper Sandler restated an "overweight" rating and set a $5.00 target price (down previously from $13.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, August 13th. Finally, StockNews.com upgraded shares of Syros Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Tuesday, October 15th.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.